Open Access<p>Combining PD-1 Inhibitor Nivolumab with Radiotherapy Successfully Treated a Patient with Refractory Primary Mediastinal Large B-Cell Lymphoma: A Case Report and Literature Review</p>
Author(s) -
Yan Zheng,
Zhi Hua Yao,
Shu Na Yao,
Xiao Qing,
Hai Ying Wang,
Jun Chu,
Ming Xu Song,
Shuang Zhao,
Yan Yan Liu
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s254007
Subject(s) - nivolumab , refractory (planetary science) , medicine , lymphoma , radiation therapy , oncology , cancer research , immunotherapy , materials science , cancer , composite material
Primary mediastinal large B-cell lymphoma (PMBCL) is relatively infrequent and generally has a good prognosis with standard immunochemotherapy. However, treatment options are limited for patients with relapsed/refractory PMBCL who are ineligible for stem cell transplantation. In this report, we treated a refractory PMBCL patient, who did not respond to salvage chemotherapy, with combined nivolumab and radiotherapy. The patient achieved a complete remission with mild adverse reactions and has survived without relapse 2 years after treatment.